News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-05-13 pm EDT			5-day change	1st Jan Change
151.2 ^USD	+0.87%		+1.78%	-3.52%

May. 13	Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe	MT
May. 13	Johnson & Johnson Offering Notes to Help Fund Shockwave Medical Acquisition	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe	May. 13	MT
Johnson & Johnson Offering Notes to Help Fund Shockwave Medical Acquisition	May. 13	MT
J&J: stake in Kenvue to be sold off	May. 13	CF
J&J to Sell Remaining Stake in Kenvue Spinoff	May. 13	DJ
Sector Update: Consumer Stocks Gain Premarket Monday	May. 13	MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes	May. 13	MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes	May. 13	MT
J&J to exit Kenvue, a year after spinoff	May. 13	RE
J&J to sell all shares in spun-off unit Kenvue	May. 13	RE
J&J: technological update in cardiac arrhythmia	May. 09	CF
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	May. 08	BU
Intravesical drug delivery system exhibits bladder cancer benefit	May. 07	AQ
Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs	May. 07	RE
Johnson & Johnson - Phase 2 data for ERLEADA plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate	May. 06	AQ
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	May. 06	AQ
Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	May. 06	AQ
J&J: encouraging results in prostate cancer	May. 06	CF
J&J: positive results in bladder cancer	May. 06	CF
Johnson & Johnson Announces Updated Results from an Open-Label, Multicenter, Multi-Cohort Phase 1 Study of the Safety and Efficacy of TAR-210	May. 05	CI
Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate	May. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST